PubMed چکیده/رکورد

NR_045396/MicroRNA761/FADD axis regulates necroptosis and survival of retinal ganglion cells.

استودیوی صوتی مقاله

پخش حرفه‌ای فارسی و انگلیسی

در حال بررسی نسخه‌های صوتی ذخیره‌شده…

صوت تولیدشده با هوش مصنوعی است. برای کاربرد علمی یا درمانی، متن و منبع اصلی را بررسی کنید.
خواندن هوشمند فارسی و انگلیسی در حال آماده‌سازی صداهای مرورگر…
تنظیم صدای طبیعی و سرعت

صداهایی که در نامشان «Natural»، «Neural» یا «Online» دیده می‌شود معمولاً طبیعی‌ترند. انتخاب صدا به صداهای نصب‌شده در ویندوز و مرورگر شما بستگی دارد.

چکیده اصلی

The involvement of necroptosis and the underlying mechanism in retinal ganglion cell (RGC) death is not fully understood. We aim to determine whether the NR_045396/miRNA761/Fas-associated protein with death domain (FADD) axis participates in the regulation of necroptosis in RGCs. A mouse model of optic nerve crush was employed for in vivo experiments. Apoptosis and necrosis were assessed by TUNEL and Propidium iodide (PI) exclusion. We found that the necrotic rate increased in a time-dependent manner in RGCs following optic nerve injury, whereas apoptosis peaked at 7 days following nerve damage. Immunohistochemistry revealed that the expression levels of key markers of necroptosis, pRIP3 and pMLKL, were upregulated, whereas FADD expression was reduced in RGCs at 14 days after optic nerve injury. Enforced expression of FADD in RGCs by an AAV vector attenuated necrotic response and promoted RGC survival. A dual-luciferase reporter gene assay showed that miR761 directly regulated FADD expression. Intraocular application of AAV2 expressing sequences complementary to miR761 binding site (AAV2-miR761 sponge) enhanced FADD expression and regulated RGC necrosis and survival. Moreover, the long non-coding RNA (lncRNA) NR_045396 binds directly to miR761 and modulates the necrotic program of RGCs. Thus, we demonstrate the anti-necroptosis and neuroprotective effects of the NR_045396/miR761/FADD axis.

متن کامل اصلی

متن در JumpToDate ذخیره نشده است.

برای بررسی دسترسی کتابخانه‌ای یا خرید، رکورد اصلی را باز کنید.

رفتن به منبع اصلی
در همین زیرشاخه

مقاله‌های مرتبط

PubMed2026

Keratin 17 immunocytochemistry in urine cytology for urothelial carcinoma detection: Diagnostic performance and interobserver agreement in a prospective real-world cohort.

BACKGROUND: Urine cytology is recommended for noninvasive detection of urothelial carcinoma (UC) but shows limited sensitivity, particularly in low-grade disease. Keratin 17 (K17) has emerged as a promising immunocytochemical marker. This study evaluated the diagnostic performance and interobserver agreement of K17 in a routine setting. METHODS: This prospective cross-sectional study included 184 urine samples from patients undergoing …

PubMed2026

A case report of primary prostate intravascular large B-cell lymphoma.

RATIONALE: Primary intravascular large B-cell lymphoma (IVLBCL) is a rare and aggressive extranodal lymphoma that rarely affects the prostate. Its nonspecific clinical and laboratory features often lead to misdiagnosis as benign prostatic hyperplasia (BPH) or prostatitis, delaying appropriate treatment. We report a case of primary prostatic IVLBCL initially misdiagnosed as BPH, highlighting the diagnostic challenges and the importance …

PubMed2026

An immunohistochemical based assessment of murine double minute 2 (MDM2) and cyclin-dependent kinase 4 (CDK4) in jaw osteosarcoma and benign osseous lesions.

UNLABELLED: The diagnosis of primary bone tumours of the jaw often presents as a diagnostic dilemma. Overlap in clinical, radiological, and histological features between benign lesions like juvenile trabecular ossifying fibroma (JTOF); osteoblastoma (OB) and malignant tumours like low-grade osteosarcoma (LGOS) makes the diagnosis challenging. While osteosarcoma is a malignant tumour with poor prognosis requiring aggressive treatment, b…

PubMed2026

The human trophoblast cell-surface antigen 2 (TROP-2) expression on metastasized breast cancer.

PURPOSE: The antibody-drug conjugates (ADCs) sacituzumab govitecan (SG) and datopotamab deruxtecan target trophoblast cell surface antigen 2 (TROP-2) and have shown significant efficacy in HER2-negative metastatic breast cancer (mBC). As TROP-2 may serve as a target across multiple treatment lines, detailed information on TROP-2 expression over time is of great interest. METHODS: TROP-2 expression was analyzed in breast cancer (BC) sam…